Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma
J Chemother. 2023 Nov 16:1-8. doi: 10.1080/1120009X.2023.2281089. Online ahead of print.ABSTRACTHodgkin Lymphoma (HL) is often curable with ABVD therapy and improving outcomes is a main goal of ongoing research. Bleomycin-associated pneumonitis (BAPT) is a potentially life-threatening complication that necessitates bleomycin discontinuation. We conducted this study on a homogenous cohort of advanced stage HL treated only with ABVD for frontline therapy to assess if bleomycin discontinuation increases the risk of lymphoma progression. After the exclusion of patients who received radiotherapy or other drugs, 106 and 28 patie...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Umut Y ılmaz G üldane Zulfaliyeva Adnan Nuri G üzelli Deniz Özmen Tu ğrul Elverdi Ay şe Salihoğlu Ahmet Emre Eskazan Şeniz Öngören Zafer Ba şlar Muhlis Cem Ar Source Type: research
Efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer: a meta-analysis of phase II and III randomized controlled trials
J Chemother. 2023 Nov 17:1-8. doi: 10.1080/1120009X.2023.2281760. Online ahead of print.ABSTRACTWe conducted a meta-analysis to evaluate the efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer. Databases were searched for relevant studies till June 2023. Six RCTs involving 1912 patients were included. The pooled analysis provided evidence that veliparib-containing regimens could significantly improve the PFS (HR: 0.71; 95% CI: 0.61-0.83; p < 0.0001), OS (HR: 0.87; 95% CI: 0.76-0.99; p = 0.03), and ORR (RR: 1.52; 95% CI:1.06-2.18; p = 0.02) than those of controls for treating advanced/m...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Wenxia Sun Jing Li Source Type: research
Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma
J Chemother. 2023 Nov 16:1-8. doi: 10.1080/1120009X.2023.2281089. Online ahead of print.ABSTRACTHodgkin Lymphoma (HL) is often curable with ABVD therapy and improving outcomes is a main goal of ongoing research. Bleomycin-associated pneumonitis (BAPT) is a potentially life-threatening complication that necessitates bleomycin discontinuation. We conducted this study on a homogenous cohort of advanced stage HL treated only with ABVD for frontline therapy to assess if bleomycin discontinuation increases the risk of lymphoma progression. After the exclusion of patients who received radiotherapy or other drugs, 106 and 28 patie...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Umut Y ılmaz G üldane Zulfaliyeva Adnan Nuri G üzelli Deniz Özmen Tu ğrul Elverdi Ay şe Salihoğlu Ahmet Emre Eskazan Şeniz Öngören Zafer Ba şlar Muhlis Cem Ar Source Type: research
Efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer: a meta-analysis of phase II and III randomized controlled trials
J Chemother. 2023 Nov 17:1-8. doi: 10.1080/1120009X.2023.2281760. Online ahead of print.ABSTRACTWe conducted a meta-analysis to evaluate the efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer. Databases were searched for relevant studies till June 2023. Six RCTs involving 1912 patients were included. The pooled analysis provided evidence that veliparib-containing regimens could significantly improve the PFS (HR: 0.71; 95% CI: 0.61-0.83; p < 0.0001), OS (HR: 0.87; 95% CI: 0.76-0.99; p = 0.03), and ORR (RR: 1.52; 95% CI:1.06-2.18; p = 0.02) than those of controls for treating advanced/m...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Wenxia Sun Jing Li Source Type: research
Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma
J Chemother. 2023 Nov 16:1-8. doi: 10.1080/1120009X.2023.2281089. Online ahead of print.ABSTRACTHodgkin Lymphoma (HL) is often curable with ABVD therapy and improving outcomes is a main goal of ongoing research. Bleomycin-associated pneumonitis (BAPT) is a potentially life-threatening complication that necessitates bleomycin discontinuation. We conducted this study on a homogenous cohort of advanced stage HL treated only with ABVD for frontline therapy to assess if bleomycin discontinuation increases the risk of lymphoma progression. After the exclusion of patients who received radiotherapy or other drugs, 106 and 28 patie...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Umut Y ılmaz G üldane Zulfaliyeva Adnan Nuri G üzelli Deniz Özmen Tu ğrul Elverdi Ay şe Salihoğlu Ahmet Emre Eskazan Şeniz Öngören Zafer Ba şlar Muhlis Cem Ar Source Type: research
Efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer: a meta-analysis of phase II and III randomized controlled trials
J Chemother. 2023 Nov 17:1-8. doi: 10.1080/1120009X.2023.2281760. Online ahead of print.ABSTRACTWe conducted a meta-analysis to evaluate the efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer. Databases were searched for relevant studies till June 2023. Six RCTs involving 1912 patients were included. The pooled analysis provided evidence that veliparib-containing regimens could significantly improve the PFS (HR: 0.71; 95% CI: 0.61-0.83; p < 0.0001), OS (HR: 0.87; 95% CI: 0.76-0.99; p = 0.03), and ORR (RR: 1.52; 95% CI:1.06-2.18; p = 0.02) than those of controls for treating advanced/m...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Wenxia Sun Jing Li Source Type: research
Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma
J Chemother. 2023 Nov 16:1-8. doi: 10.1080/1120009X.2023.2281089. Online ahead of print.ABSTRACTHodgkin Lymphoma (HL) is often curable with ABVD therapy and improving outcomes is a main goal of ongoing research. Bleomycin-associated pneumonitis (BAPT) is a potentially life-threatening complication that necessitates bleomycin discontinuation. We conducted this study on a homogenous cohort of advanced stage HL treated only with ABVD for frontline therapy to assess if bleomycin discontinuation increases the risk of lymphoma progression. After the exclusion of patients who received radiotherapy or other drugs, 106 and 28 patie...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Umut Y ılmaz G üldane Zulfaliyeva Adnan Nuri G üzelli Deniz Özmen Tu ğrul Elverdi Ay şe Salihoğlu Ahmet Emre Eskazan Şeniz Öngören Zafer Ba şlar Muhlis Cem Ar Source Type: research
Efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer: a meta-analysis of phase II and III randomized controlled trials
J Chemother. 2023 Nov 17:1-8. doi: 10.1080/1120009X.2023.2281760. Online ahead of print.ABSTRACTWe conducted a meta-analysis to evaluate the efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer. Databases were searched for relevant studies till June 2023. Six RCTs involving 1912 patients were included. The pooled analysis provided evidence that veliparib-containing regimens could significantly improve the PFS (HR: 0.71; 95% CI: 0.61-0.83; p < 0.0001), OS (HR: 0.87; 95% CI: 0.76-0.99; p = 0.03), and ORR (RR: 1.52; 95% CI:1.06-2.18; p = 0.02) than those of controls for treating advanced/m...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Wenxia Sun Jing Li Source Type: research
Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma
J Chemother. 2023 Nov 16:1-8. doi: 10.1080/1120009X.2023.2281089. Online ahead of print.ABSTRACTHodgkin Lymphoma (HL) is often curable with ABVD therapy and improving outcomes is a main goal of ongoing research. Bleomycin-associated pneumonitis (BAPT) is a potentially life-threatening complication that necessitates bleomycin discontinuation. We conducted this study on a homogenous cohort of advanced stage HL treated only with ABVD for frontline therapy to assess if bleomycin discontinuation increases the risk of lymphoma progression. After the exclusion of patients who received radiotherapy or other drugs, 106 and 28 patie...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Umut Y ılmaz G üldane Zulfaliyeva Adnan Nuri G üzelli Deniz Özmen Tu ğrul Elverdi Ay şe Salihoğlu Ahmet Emre Eskazan Şeniz Öngören Zafer Ba şlar Muhlis Cem Ar Source Type: research
Efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer: a meta-analysis of phase II and III randomized controlled trials
J Chemother. 2023 Nov 17:1-8. doi: 10.1080/1120009X.2023.2281760. Online ahead of print.ABSTRACTWe conducted a meta-analysis to evaluate the efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer. Databases were searched for relevant studies till June 2023. Six RCTs involving 1912 patients were included. The pooled analysis provided evidence that veliparib-containing regimens could significantly improve the PFS (HR: 0.71; 95% CI: 0.61-0.83; p < 0.0001), OS (HR: 0.87; 95% CI: 0.76-0.99; p = 0.03), and ORR (RR: 1.52; 95% CI:1.06-2.18; p = 0.02) than those of controls for treating advanced/m...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Wenxia Sun Jing Li Source Type: research
Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma
J Chemother. 2023 Nov 16:1-8. doi: 10.1080/1120009X.2023.2281089. Online ahead of print.ABSTRACTHodgkin Lymphoma (HL) is often curable with ABVD therapy and improving outcomes is a main goal of ongoing research. Bleomycin-associated pneumonitis (BAPT) is a potentially life-threatening complication that necessitates bleomycin discontinuation. We conducted this study on a homogenous cohort of advanced stage HL treated only with ABVD for frontline therapy to assess if bleomycin discontinuation increases the risk of lymphoma progression. After the exclusion of patients who received radiotherapy or other drugs, 106 and 28 patie...
Source: Journal of Chemotherapy - November 17, 2023 Category: Cancer & Oncology Authors: Umut Y ılmaz G üldane Zulfaliyeva Adnan Nuri G üzelli Deniz Özmen Tu ğrul Elverdi Ay şe Salihoğlu Ahmet Emre Eskazan Şeniz Öngören Zafer Ba şlar Muhlis Cem Ar Source Type: research
